Search Results - john+davies

2 Results Sort By:
Tiered Screening of Therapeutic TCRs for Identification of Autoimmune Cross-Reactivity
Summary: The National Cancer Institute seeks research co-development partners and/or licensees for a standardized method of detecting T-cell receptor (TCR) cross-reactivity as a means of proving safety and efficacy in preclinical evaluations ahead of clinical trials. Description of Technology: TCR-based therapies targeting cancer-associated antigens...
Published: 4/8/2024   |   Inventor(s): Kazusa Ishii, Christian Hinrichs, John Davies
Keywords(s):  
Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Research Materials, Application > Therapeutics
Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain
Abstract: Immunotherapy is a cutting-edge new category of treatment that aims to harness and, in some cases, modify the patient’s own immune cells to improve their ability to cure diseases. It can be an effective approach for a variety of conditions, ranging from cancer to inflammatory diseases.  However, a number of obstacles to the overall success...
Published: 4/8/2024   |   Inventor(s): Paul Love, Guillaume Gaud, Christian Hinrichs, John Davies
Keywords(s): CD3, Davies, Eunice Kennedy Shriver National Institute of Child Health an, Gaud, Hinrichs, Immuno-receptor Tyrosine-based Activation Motif, Immunotherapy, ITAM, Love, National Cancer Institute, Nci, NICHD, T Cell Receptor, TCR, Zeta Chain
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology
© 2024. All Rights Reserved. Powered by Inteum